Core Viewpoint - Rebio Biotech-B (06938) has successfully listed its shares at a price of HKD 57.97, raising approximately HKD 1.702 billion, with a notable initial increase of 29.38% to HKD 75 per share [1] Company Overview - Rebio Biotech is focused on the research and development of small nucleic acid drugs, particularly specializing in siRNA therapies [1] - The company has a core product, RBD4059, aimed at treating thrombotic diseases, and has a pipeline of seven self-developed drug assets currently in clinical trials [1] Clinical Pipeline - The clinical pipeline includes treatments for cardiovascular, metabolic, renal, and liver diseases, with four products currently in Phase 2 clinical trials [1] - In addition to RBD4059, the company is advancing other clinical-stage products such as RBD5044 and RBD1016 [1] - RBD5044 is the second siRNA drug globally to enter clinical development targeting APOC3, a protein involved in lipid metabolism [1] - RBD1016 aims for functional cure of chronic hepatitis B (CHB) through its action on HBsAg and is a differentiated siRNA candidate for coronary heart disease (CHD) [1] Preclinical Projects - Beyond the clinical pipeline, the company has over 20 preclinical projects planned for advancement into clinical development [1]

专注癌症药物研发的生物科技公司Revolution Medicines(RVMD.US)夜盘涨超13%，报121.5美元。消息 面上，据英国《金融时报》引述知情人士称，默沙东正就收购Revolution Medicines进行磋商。报道称， 交易作价或介乎280亿至320亿美元，若最终落实，将成为自2023年底辉瑞以430亿美元收购Seagen以 来，规模最大的药业并购之一。此前艾伯维否认正在洽谈收购Revolution Medicines。 ...

Group 1 - The core viewpoint of the article is that Rebio Pharmaceuticals-B (6938.HK) is set to be listed on the Hong Kong Stock Exchange tomorrow, with significant interest shown in pre-listing trading [1] - In dark pool trading today, the stock price surged nearly 40%, reaching HKD 81, indicating strong market demand [1] - Each trading lot consists of 200 shares, allowing investors to potentially earn HKD 4,606 per lot, highlighting the lucrative opportunity for early investors [1] Group 2 - Rebio Pharmaceuticals specializes in the research and development of small nucleic acid drugs, particularly focusing on siRNA therapies, positioning itself as a pioneer in this field since its inception in 2007 [1]

Group 1: Precious Metals Market - The prices of precious metals have sharply declined, with international gold prices dropping nearly $70 in a single day, and silver, platinum, and palladium experiencing declines of over 4% [2] - Following the largest annual increase since 1979, investors are opting to take profits, as indicated by a reduction in net long positions for gold and silver by 10,668 contracts to 126,873 and by 7,270 contracts to 16,595, respectively [3] - The upcoming rebalancing of the Bloomberg Commodity Index is expected to trigger panic selling in the market, with significant weight reductions for gold and silver [4][6] Group 2: Index Rebalancing Impact - The Bloomberg Commodity Index will undergo annual weight adjustments starting January 8, with gold's weight decreasing from 19.6% to 14.9% and silver's from 7.7% to 3.9% [5][6] - This weight reduction implies substantial passive selling, with Citigroup estimating that the sell-off for both gold and silver could reach around $7 billion each [7] Group 3: Insurance Capital and Stock Market - Insurance capital is increasingly engaging in stock purchases, with a notable example being Ping An Life's announcement of a 20% stake in Agricultural Bank of China H-shares, marking its fourth stake increase [8][9] - In 2025, insurance capital made 35 stake increases, the highest since 2016, with the allocation to stocks reaching 3.6 trillion yuan, accounting for 10% of total insurance funds [10] Group 4: Motivations Behind Insurance Capital Activity - Three core motivations for the concentrated stake increases by insurance capital include the need to enhance returns amid low interest rates, accounting changes that stabilize profit reporting, and policy support for long-term capital market investments [11] Group 5: Foreign Investment in Chinese Assets - Foreign investment giants are also increasing their positions in Chinese assets, with BlackRock raising stakes in several Hong Kong stocks on the first trading day of 2026 [12][13] - Goldman Sachs forecasts a 20% increase in the MSCI China Index and a 12% increase in the CSI 300 Index for 2026, predicting a net inflow of $200 billion from southbound funds [14] Group 6: Retail Investor Trends - The number of new retail investors in the A-share market reached 27.44 million in 2025, a 9.75% increase from 2024, marking the highest annual figure since 2022 [14] - Personal investors remain the primary source of new accounts, while institutional investor accounts saw a significant increase, with a 35% year-on-year growth [15]

责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 香港联交所最新资料显示，1月2日，小摩增持信达生物（01801）317.3036万股，每股作价78.4477港 元，总金额约为2.49亿港元。增持后最新持股数目约为8895.73万股，最新持股比例为5.16%。 香港联交所最新资料显示，1月2日，小摩增持信达生物（01801）317.3036万股，每股作价78.4477港 元，总金额约为2.49亿港元。增持后最新持股数目约为8895.73万股，最新持股比例为5.16%。 责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 ...

| 股份代號: | 01801 | | --- | --- | | 上市法國名稱: | 信建生物製藥 | | 日期(日 / 月 / 年): | 09/12/2025 - 09/01/2026 | | 豪格序號 | 大股東/董事/最高行政人員名稱 作出披露的 買入 / 賣出或涉及的股 每股的平均價 | | | 持有權益的股份數目 佔已發行的 有關事件的 | | --- | --- | --- | --- | --- | | | 分野信 | | | ( 謂參閱工処 註解 ) 月 反宗 催版 ( | | | | | | 份自分厨 | | | | | | 9/0 | | CS20260107E00514 | JPMorgan Chase & Co. 3,173,036(L) | 1001(L) | HKD 78.4477 | 88.957.269(L) 5.16(L)02/01/2026 | | | | | | 10,589,119(S) 0.61(S) | | | | | | 69,463,021(P) 4.03(P) | 格隆汇1月9日丨根据联交所最新权益披露资料显示，2026年1月2日，信达生物(01801.H ...

Core Viewpoint - Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. has received a notice of acceptance from the National Medical Products Administration for the conditional approval of the drug registration application for GR1803 injection, which is intended for adult patients with relapsed or refractory multiple myeloma who have previously received at least three lines of treatment [1] Group 1: Drug Information - Drug Name: GR1803 Injection [1] - Application Type: Domestic drug registration application [1] - Applicant: Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. [1] - Acceptance Number: CXSS2600003 [1] - Approval Conclusion: The application has been accepted based on the review [1] Group 2: Disease Context - Multiple myeloma (MM) is a malignant disease characterized by the abnormal proliferation of clonal plasma cells, primarily affecting the elderly [2] - Common symptoms include organ dysfunction related to myeloma, such as elevated blood calcium, kidney damage, anemia, and bone diseases [2] - MM is the second most common malignant tumor in the blood system, with an increasing incidence rate in recent years, particularly among individuals aged 60 and above [2] Group 3: Drug Characteristics - GR1803 Injection is a bispecific antibody drug developed by the company, targeting BCMA and CD3, classified as a Class 1 therapeutic biological product [3] - The drug is based on a common light chain structure, which is similar to normal monoclonal antibody structures, facilitating its production and reducing potential immunogenicity [3] - GR1803 Injection has a higher affinity for BCMA (10^-10 M) compared to CD3 (10^-8 M), designed to activate T cells to kill tumor cells while minimizing non-specific T cell activation and reducing toxicity [3] - As of the announcement date, two imported BCMA×CD3 targeted antibody drugs have been conditionally approved for market in China [3]

Core Viewpoint - Suzhou Zejing Biopharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for its self-developed injectable recombinant human thyroid-stimulating hormone beta (rhTSH), marking it as the first innovative product approved in China for precise assessment post-surgery in differentiated thyroid cancer patients [2][3]. Drug Basic Information - Injectable human thyroid-stimulating hormone beta (rhTSH) is a biopharmaceutical developed by the company, belonging to the category of therapeutic biological products. It mimics the endogenous thyroid-stimulating hormone in humans and is designed to stimulate iodine uptake and the synthesis and release of thyroid hormones [3]. Clinical Research Results - A Phase III clinical study demonstrated that the consistency rate of whole-body imaging scan (WBS) results after rhTSH administration was 88.2%. In patients with negative thyroglobulin antibodies, the consistency rate for two-stage thyroglobulin assessment was 90.4% [4]. - The study also indicated that rhTSH administration significantly reduced symptoms of hypothyroidism compared to stopping thyroid hormone therapy, improving the quality of life for patients [4]. Market Collaboration - In June 2025, the company entered into a collaboration agreement with Merck, granting them exclusive marketing rights for rhTSH within mainland China, excluding Hong Kong, Macau, and Taiwan [5]. Impact on Company - The approval of rhTSH is expected to enrich the company's product line and positively impact its future operating performance [5].

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Simcere Zaiming Pharmaceutical Co., Ltd. 先聲再明醫藥股份有限公司 (A joint stock company with limited liability incorporated in ...

Financial Data and Key Metrics Changes - The meeting reported that proxies were received for 961,887 of the 2,277,139 shares of common stock outstanding, representing approximately 42% of the total shares, which unfortunately does not constitute a quorum for business transactions [3]. Company Strategy and Development Direction - The company has adjourned the annual stockholders' meeting due to the lack of quorum, indicating a need for further engagement with shareholders to ensure participation in future meetings [4]. Other Important Information - The company will determine a new date and time to hold the 2025 annual stockholders' meeting, reflecting ongoing efforts to maintain communication with stakeholders [4]. Summary of Q&A Session - No questions or answers were recorded during this meeting as it was adjourned due to the lack of quorum [3][4].